Renaissance Technologies (RenTech)'s ARQT Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC) currently holds 476,099 shares of Arcutis Biotherapeutics, Inc. (ARQT) worth $12.58 M, representing 0.02% of the portfolio. First purchased in 2020-Q2, this medium-term investment has been held for 15 quarters.
Based on 13F filings, Renaissance Technologies (RenTech) has maintained a strategic position in ARQT, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2026, adding 417,700 shares. Largest reduction occurred in Q1 2024, reducing 395,100 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s Arcutis Biotherapeutics (ARQT) Holding Value Over Time
Track share changes against reported price movement
Quarterly Arcutis Biotherapeutics (ARQT) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q3 2026 | +417,700 | Add 715.25% | 476,099 | $26.43 |
| Q2 2026 | -382,600 | Reduce 86.76% | 58,399 | $26.22 |
| Q1 2026 | +167,000 | Add 60.95% | 440,999 | $23.56 |
| Q4 2025 | +273,999 | New Buy | 273,999 | $29.04 |
| Q2 2025 | -21,799 | Sold Out | 0 | $0.00 |
| Q1 2025 | +10,700 | Add 96.41% | 21,799 | $15.64 |
| Q4 2024 | -181,000 | Reduce 94.22% | 11,099 | $13.93 |
| Q3 2024 | +192,099 | New Buy | 192,099 | $9.30 |
| Q1 2024 | -395,100 | Sold Out | 0 | $0.00 |
| Q4 2023 | +395,100 | New Buy | 395,100 | $3.23 |
| Q4 2022 | -65,000 | Sold Out | 0 | $0.00 |
| Q3 2022 | +54,200 | Add 501.85% | 65,000 | $19.11 |
| Q2 2022 | +10,800 | New Buy | 10,800 | $21.30 |
| Q3 2020 | -27,700 | Sold Out | 0 | $0.00 |
| Q2 2020 | +27,700 | New Buy | 27,700 | $30.25 |
Renaissance Technologies (RenTech)'s Arcutis Biotherapeutics Investment FAQs
Renaissance Technologies (RenTech) first purchased Arcutis Biotherapeutics, Inc. (ARQT) in Q2 2020, acquiring 27,700 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held Arcutis Biotherapeutics, Inc. (ARQT) for 15 quarters since Q2 2020.
Renaissance Technologies (RenTech)'s largest addition to Arcutis Biotherapeutics, Inc. (ARQT) was in Q3 2026, adding 476,099 shares worth $12.58 M.
According to the latest 13F filing for Q3 2026, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC, owns 476,099 shares of Arcutis Biotherapeutics, Inc. (ARQT), valued at approximately $12.58 M.
As of the Q3 2026 filing, Arcutis Biotherapeutics, Inc. (ARQT) represents approximately 0.02% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in Arcutis Biotherapeutics, Inc. (ARQT) was 476,099 shares, as reported at the end of Q3 2026.